Goldman Sachs maintains neutral on SAGE stock amid dalzanemdor setback

Retrieved on: 2024-04-17 15:06:02

Tags for this article:

Click the tags to see associated articles and topics

Goldman Sachs maintains neutral on SAGE stock amid dalzanemdor setback. View article details on hiswai:

Excerpt

On Wednesday, Goldman Sachs affirmed its Neutral stance on shares of Sage Therapeutics (NASDAQ:SAGE), maintaining a price target of $28.00.

Article found on: www.investing.com